Home / Press / Bruker Corporation advised by CMS on acquisition of...

Bruker Corporation advised by CMS on acquisition of majority stake in diagnostics firm Hain Lifescience

24/08/2018

Frankfurt/Main – Bruker Corporation, a US tech company in the analytical instrumentation sector, has acquired a majority shareholding in Hain Lifescience GmbH. Hain Lifescience specialises in molecular diagnostics, particularly for infectious diseases. The transaction is currently awaiting approval from the competition authorities, among other factors. The parties have agreed not to disclose the purchase price.

An international CMS team headed by Dr Hendrik Hirsch advised Bruker Corporation on all legal aspects of the transaction. In addition to negotiating the transaction, the advice related to structuring the future relationship between Bruker as the majority shareholder and some of the sellers as future minority shareholders, legal due diligence and coordination of an international team from the UK, France, Spain, South Africa and Norway. Bruker Corporation is a longstanding client of CMS Germany and has been advised by CMS on several acquisitions in the past.

Bruker Corporation is an international manufacturer of scientific instruments and high-end analytical and diagnostic equipment for pharmaceuticals/biotech, clinical diagnostics and industry. Headquartered in Billerica, Massachusetts (USA), the company employs more than 6,000 people across some 90 locations worldwide. NASDAQ-listed Bruker Corporation posted sales of around USD 1.77 billion in 2017. In acquiring Hain Lifescience, the company is seeking to expand its presence in the markets for infectious diseases and molecular diagnostics.

Hain Lifescience GmbH, which is headquartered in Nehren near Tübingen, develops and markets test systems and equipment for diagnostic laboratories. The molecular genetic test systems enable a number of different pathogens and their resistances to be detected, for example MRSA and tuberculosis bacteria. The company has more than 100 employees and a worldwide network of distributors, together with its own subsidiaries in Spain, the UK, France, South Africa and Kenya. Hain Lifescience expects sales of around USD 38 million in 2018.

CMS Germany

Dr Hendrik Hirsch, Lead Partner
Dr Holger Pattberg, Counsel
Dr Berrit Roth-Mingram, Associate, all Corporate/M&A
Marcus Fischer, Counsel, Tax
Dr Andreas Hofelich, Partner
Dr Boris Alles, Senior Associate
Laura Matarrelli, Senior Associate, all Labor, Employment & Pensions
Dr Thomas Hirse, Partner, Intellectual Property
Dr Joachim Kaetzler, Partner
Ivonne Kahlke, Associate, both Compliance

CMS France

Jean-Robert Bousquet, Partner
Romain Boyet, Senior Associate, both Corporate/M&A
Alain Herrmann, Partner, Labor & Employment

CMS Spain

Luis Miguel de Dios, Partner
Tobías Kálnay, Associate, both Corporate/M&A

CMS UK

Graeme Bruce, Partner
Jamie Gordon, both Corporate/M&A

Press Contact
[email protected] 

Related people

Hendrik Hirsch
Dr. Hendrik Hirsch
Partner
Frankfurt
Berrit Roth-Mingram
Dr. Berrit Roth-Mingram, M.A. (Sinologie)
Senior Associate
Frankfurt
Andreas Hofelich
Dr. Andreas Hofelich
Partner
Cologne
Boris Alles
Dr. Boris Alles
Counsel
Frankfurt
Laura Matarrelli
Laura Matarrelli
Counsel
Frankfurt
Thomas Hirse
Dr. Thomas Hirse
Partner
Duesseldorf
Joachim Kaetzler
Dr. Joachim Kaetzler
Partner
Frankfurt
Ivonne Kahlke
Ivonne Kahlke
Senior Associate
Frankfurt
Dr. Holger Pattberg
Marcus Fischer, Dipl.-Finanzwirt (FH)
Picture of Jean Robert Bousquet
Jean-Robert Bousquet
Partner
Paris
Alain Hermann
Alain Herrmann
Partner
Paris
Luis Miguel de Dios
Luis Miguel de Dios
Partner
Madrid
Tobías Kálnay
Bruce Graeme
Graeme Bruce
Partner
Glasgow
Jamie Gordon
Show more Show less